Analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Stock Performance
Shares of CYCC stock opened at $0.91 on Friday. The firm’s 50 day moving average price is $1.20 and its 200-day moving average price is $1.68. Cyclacel Pharmaceuticals has a one year low of $0.90 and a one year high of $11.34. The firm has a market cap of $1.34 million, a P/E ratio of -0.04 and a beta of 0.51.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative net margin of 21,963.75% and a negative return on equity of 1,901.11%. During the same period last year, the company posted ($6.60) EPS. As a group, research analysts predict that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.
Institutional Investors Weigh In On Cyclacel Pharmaceuticals
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Recommended Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- What is a SEC Filing?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- The Role Economic Reports Play in a Successful Investment Strategy
- MarketBeat Week in Review – 9/30 – 10/4
- Following Congress Stock Trades
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.